Status:
RECRUITING
The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)
Lead Sponsor:
Ruijin Hospital
Collaborating Sponsors:
RenJi Hospital
Huashan Hospital
Conditions:
IgA Nephropathy
Eligibility:
All Genders
Brief Summary
1. Establish an IgAN cohort collaboration group and expert committee to carry out registration research. 2. Construct IgAN structured data set standards, formulate structured data collection templates...
Detailed Description
Primary IgA nephropathy (IgAN) is the most common form of glomerulonephritis in China and the world. It is the main reason for Chinese young people's renal failure. The main difficulties in clinical I...
Eligibility Criteria
Inclusion
- No age limit, no gender limit;
- Kidney biopsy confirmed primary IgA nephropathy;
- Sign the informed consent form voluntarily
Exclusion
- IgA nephropathy is secondary to systemic diseases such as systemic lupus erythematosus and allergic purpura;
- IgAN is clinically diagnosed but not confirmed by pathology;
- The patient refuses to participate;
- Patients judged by other investigators to be unsuitable for inclusion in the study.
Key Trial Info
Start Date :
December 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2024
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT04858724
Start Date
December 1 2020
End Date
June 30 2024
Last Update
May 28 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ruijin Hospital, Shanghai JiaoTong University School of Medicine
Shanghai, Shanghai Municipality, China, 200025